Singh, Dave
Wild, Jim M.
Saralaya, Dinesh
Lawson, Rod
Marshall, Helen
Goldin, Jonathan
Brown, Matthew S.
Kostikas, Konstantinos
Belmore, Kristin
Fogel, Robert
Patalano, Francesco
Drollmann, Anton
Machineni, Surendra
Jones, Ieuan
Yates, Denise
Tillmann, Hanns-Christian
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
https://doi.org/10.1186/s12931-022-01949-3
Funding for this research was provided by:
Novartis Pharma AG, Basel
Article History
Received: 12 August 2021
Accepted: 3 February 2022
First Online: 10 February 2022
Declarations
:
: The study was conducted according to the ethical principles of the Declaration of Helsinki. Informed consent was obtained from all the study participants prior to initiation.
: Not applicable.
: Dave Singh reports personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Teva, Theravance, and Verona, outside the submitted work.